Navas, FranciscoChocarro-Calvo, AnaIglesias-Hernandez, PatriciaIglesias-Hernandez, PatriciaFernández-García, PalomaMorales, VictoriaGarcía-Martínez, José ManuelSanz, RaúlDe la Vieja, AntonioGarcía-Jiménez, CustodiaGarcía-Muñoz, Rafael A2024-11-202024-11-202024-04-25J Med Chem. 2024 Apr 25;67(8):6410-6424.0022-2623https://hdl.handle.net/20.500.12105/25544We report two novel prodrug Pt(IV) complexes with bis-organosilane ligands in axial positions: -dichloro(diamine)--[3-(triethoxysilyl)propylcarbamate]platinum(IV) (Pt(IV)-biSi-1) and -dichloro(diisopropylamine)--[3-(triethoxysilyl) propyl carbamate]platinum(IV) (Pt(IV)-biSi-2). Pt(IV)-biSi-2 demonstrated enhanced cytotoxicity against colon cancer cells (HCT 116 and HT-29) compared with cisplatin and Pt(IV)-biSi-1. Notably, Pt(IV)-biSi-2 exhibited higher cytotoxicity toward cancer cells and lower toxicity on nontumorigenic intestinal cells (HIEC6). In preclinical mouse models of colorectal cancer, Pt(IV)-biSi-2 outperformed cisplatin in reducing tumor growth at lower concentrations, with reduced side effects. Mechanistically, Pt(IV)-biSi-2 induced permanent DNA damage independent of p53 levels. DNA damage such as double-strand breaks marked by histone gH2Ax was permanent after treatment with Pt(IV)-biSi-2, in contrast to cisplatin's transient effects. Pt(IV)-biSi-2's faster reduction to Pt(II) species upon exposure to biological reductants supports its superior biological response. These findings unveil a novel strategy for designing Pt(IV) anticancer prodrugs with enhanced activity and specificity, offering therapeutic opportunities beyond conventional Pt drugs.engVoRhttp://creativecommons.org/licenses/by/4.0/AnimalsAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorHT29 CellsHumansLigandsMiceOrganoplatinum CompoundsProdrugsSilanesStructure-Activity RelationshipAttribution 4.0 International385920146786410-642410.1021/acs.jmedchem.3c023931520-4804Journal of medicinal chemistryopen access